Evidence map›Paper›PMID 33093900›Full record

ArticleExperimental and therapeutic medicine2020

Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere

Daniel A Benisek, Julio Manzitti, Daniel Scorsetti, Andres M Rousselot Ascarza, Amalia A Ascarza, Diego Gomez Rancaño, Romina Quercia, Matias Ramirez Gismondi, Mateo A Carpio Total, María L Scorsetti and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03668054 (Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03668054 phase3completednot on this map

Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration.

TypeinterventionalSponsorLaboratorio Elea Phoenix S.A.Ran2017 to 2018Enrolled22ConditionsAge-Related Macular DegenerationArmsBevacizumab (Lumiere®)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daniel A BenisekConsultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, C1115ABB Buenos Aires, Argentina.
Julio ManzittiConsultorio Oftalmológico Julio Manzitti, Ciudad Autonóma de Buenos Aires, C1124AAG Buenos Aires, Argentina.
Daniel ScorsettiInstituto Scorsetti, Ciudad Autónoma de Buenos Aires, C1120AAC Buenos Aires, Argentina.
Andres M Rousselot AscarzaConsultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, C1115ABB Buenos Aires, Argentina.
Amalia A AscarzaConsultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, C1115ABB Buenos Aires, Argentina.
Diego Gomez RancañoConsultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, C1115ABB Buenos Aires, Argentina.
Romina QuerciaConsultorio Oftalmológico Julio Manzitti, Ciudad Autonóma de Buenos Aires, C1124AAG Buenos Aires, Argentina.
Matias Ramirez GismondiConsultorio Oftalmológico Julio Manzitti, Ciudad Autonóma de Buenos Aires, C1124AAG Buenos Aires, Argentina.
Mateo A Carpio TotalInstituto Scorsetti, Ciudad Autónoma de Buenos Aires, C1120AAC Buenos Aires, Argentina.
María L ScorsettiInstituto Scorsetti, Ciudad Autónoma de Buenos Aires, C1120AAC Buenos Aires, Argentina.
Eduardo SpitzerClinical Research Department, Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.
Carola LombasClinical Research Department, Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.
Matías DepratiHealth Department, Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.
María Ines PennaHealth Department, Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.
Francisco FernándezPharmacovigilance Department Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.
Marcelo A TinelliClinical Research Department, Laboratorio Elea-Phoenix S.A., Los Polvorines, B1613AUE Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was an open-label, prospective, uncontrolled and multicenter clinical trial to investigate the safety and effectiveness of bevacizumab (Lumiere

Indexed as

bevacizumabcentral retinal thicknessintravitreal anti-VEGF therapyneovascular age-related macular degenerationvisual acuity

Identifiers

PMID33093900
PMCPMC7571337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.